Original Article

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience
  • Mahmut Kaya
  • Taylan Öztürk
  • Nilüfer Koçak
  • Betül Akbulut Yağcı
  • Ferdane Ataş
  • Süleyman Kaynak
Turk J Ophthalmol 2023; 53: 30-36 DOI: 10.4274/tjo.galenos.2022.38227 PMID:36847631
Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
  • Tuncay Topal
  • Taner Kar
  • Yıldıray Yıldırım
  • Sercan Koray Sağdıç
  • Cihan Büyükavşar
  • Abdullah Kaya
  • Ali Ayata
  • Murat Sönmez
  • Melih Hamdi Ünal
Turk J Ophthalmol 2017; 47: 133-137 DOI: 10.4274/tjo.34735 PMID:28630787
Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
  • Pelin Kıyat
  • Jale Menteş
  • Serhad Nalçacı
  • Filiz Afrashi
  • Mine Barış
Turk J Ophthalmol 2021; 51: 161-168 DOI: 10.4274/tjo.galenos.2020.52460 PMID:34187151
Survey of Intravitreal Injection Preferences for the Treatment of Age-Related Macular Degeneration and Macular Edema Among Members of the Turkish Ophthalmological Association
  • V. Levent Karabaş
  • Ecem Önder Tokuç
  • Figen Şermet
Turk J Ophthalmol 2022; 52: 179-185 DOI: 10.4274/tjo.galenos.2021.37075 PMID: 35770184

Case Report

Intravitreal Aflibercept as an Adjunct to Systemic Therapy in a Case of Choroidal Neovascular Membrane Associated with Sympathetic Ophthalmia
  • Ali Osman Saatçi
  • Ziya Ayhan
  • Şefik Can İpek
  • Meltem Söylev Bajin
Turk J Ophthalmol 2018; 48: 209-211 DOI: 10.4274/tjo.09076 PMID:30202619